Bibliography
- Evans WE , RellingMV: Pharmacogenomics: translating functional genomics into rational therapeutics.Science286(5439), 487–491 (1999).
- van Ede AE , LaanRF, BlomHJ et al.: The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.Arthritis Rheum.44(11), 2525–2530 (2001).
- Black AJ , McLeodHL, CapellHA et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.Ann. Intern. Med.129, 716–718 (1998).
- • Describes the predictive power of the TPMT polymorphisms on AZA toxicity.
- Grell M , DouniE, WajantH et al.: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.Cell.83, 793–802 (1995).
- Bayley JP , OttenhoffTH, VerweijCL: Is there a future for TNF promoter polymorphisms? Genes Immun.5, 315–329 (2004).
- • An excellent review focussing on the controversies surrounding the functional role of the TNF promoter polymorphisms.
- Louis E , FranchimontD, PironA et al.: Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans.Clin. Exp. Immunol.113, 401–406 (1998).
- Tang GJ , HuangSL, YienHW et al.: Tumor necrosis factor gene polymorphism and septic shock in surgical infection (see comment).Crit. Care Med.28, 2733–2736 (2000).
- Bouma G , CrusiusJB, Oudkerk Pool M et al.: Secretion of tumor necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J. Immunol.43, 456–463 (1996).
- Allen RD : Polymorphism of the human TNF-α promoter-random variation or functional diversity?Mol. Immunol.36, 1017–1027 (1999).
- Knight JC , KeatingBJ, RockettKA, KwiatkowskiDP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading (see comment).Nature Genet.33, 469–475 (2003).
- Huizinga TW , WestendorpRG, BollenEL et al.: TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.J. Neuroimmunol.72, 149–153 (1997).
- Fabris M , DiPE, D’EliaA et al.: Tumor necrosis factor-α gene polymorphism in severe and mild-moderate rheumatoid arthritis.J. Rheumatol.29, 29–33 (2002).
- Udalova IA , NedospasovSA, WebbGC et al.: Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 16,180–186 (1993).
- Cope AP , AderkaD, DohertyM et al.: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.Arthritis Rheum.35, 1160–1169 (1992).
- Morita C , HoriuchiT, TsukamotoH et al.: Association of tumor necrosis factor receptor Type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis.Arthritis Rheum.44(12), 2819–2827 (2001).
- Santee SM , Owen-SchaubLB: Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization.J. Biol. Chem.271, 21151–21159 (1996).
- Bathon JM , MartinRW, FLeischmannRM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis (see comment)(erratum appears in N. Engl. J. Med. 344[3], 240 [2001]). N. Engl. J. Med.343(22), 1586–1593 (2000).
- Lipsky PE , van der Heijde DM, St Clair EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group (see comment). N. Engl. J. Med.343(22),1594–1602 (2000).
- Kuiper S , JoostenLA, BendeleAM et al.: Different roles of tumor necrosis factor α and interleukin-1 in murine streptococcal cell wall arthritis.Cytokine10, 690–702 (1998).
- Dinarello CA , WolffSM: The role of interleukin-1 in disease (erratum appears in N. Engl. J. Med. 328[10], 744 [1993]).N. Engl. J. Med.328, 106–113 (1993).
- Bertolini DR , NedwinGE, BringmanTS et al.: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature319, 516–518 (1986).
- Saklatvala J : Tumor necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage.Nature322, 547–549 (1986).
- Scallon BJ , MooreMA, TrinhH et al.: Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions.Cytokine7, 251–259 (1995).
- Van den Brande JM, Braat H, van den Brink GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn’s disease (see comment). Gastroenterology124, 1774–1785 (2003).
- Gudbrandsdottir S , LarsenR, SorensenLK et al.: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.Clin. Exp. Rheum.22, 118–124 (2004).
- Buch MH , ConaghanPG, QuinnMA et al.: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α?Ann. Rheum. Dis.63, 1344–1346 (2004).
- van V ollenhoven R, Harju A, Brannemark S, Klareskog L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor α blockers can make sense (see comment). Ann. Rheum. Dis.62, 1195–1198 (2003).
- Weinblatt ME , KremerJM, BankhurstAD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate (see comment). N. Engl. J. Med.340(4),253–259 (1999).
- Maini RN , BreedveldFC, KaldenJR et al.: Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (see comment).Arthritis Rheum.41, 1552–1563 (1998).
- Keystone EC , KavanaughAF, SharpJT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum.50, 1400–1411 (2004).
- Wong JB : Cost-effectiveness of antitumor necrosis factor agents.Clin. Exp. Rheum.22, S65–S70 (2004).
- Mugnier B , BalandraudN, DarqueA et al.: Polymorphism at position -308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis.Arthritis Rheum.48, 1849–1852 (2003).
- Barrera P , JoostenLA, den Broeder AA et al.: Effects of treatment with a fully human antitumor necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin-1 and TNF-α in patients with rheumatoid arthritis. Ann. Rheum. Dis.60, 660–669 (2001).
- Cuchacovich M , FerreiraL, AlisteM et al.: Tumor necrosis factor-α (TNF-α) levels and influence of -308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.Scand. J. Rheumatol.33, 228–232 (2004).
- Fabris M , TolussoB, Di Poi E et al.: Tumor necrosis factor-α receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J. Rheumatol.29(9), 1847–1850 (2002).
- Padyukov L , LampaJ, HeimburgerM et al.: Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis.Ann. Rheum. Dis.62, 526–529 (2003).
- Gregersen PK , SilverJ, WinchesterRJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.Arthritis Rheum.30, 1205–1213 (1987).
- • A landmark paper describing the influence of specific MHC alleles, the shared epitope alleles on susceptibility to RA.
- Waldron-Lynch F , AdamsC, AmosC et al.: Tumor necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families.Genes Immun.2, 82–87 (2001).
- Mulcahy B , Waldron-LynchF, McDermott MF et al.: Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am. J. Hum. Genet.59, 676–683 (1996).
- Martinez A , SalidoM, BonillaG et al.: Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients (see comment).Arthritis Rheum.50(4),1077–1082 (2004).
- Criswell LA , LumRF, TurnerKN et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.Arthritis Rheum.50, 2750–2756 (2004).
- Anonymous: C omplete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium (see comment). Nature401, 921–923 (1999).
- Walsh EC , MatherKA, SchaffnerSF et al.: An integrated haplotype map of the human major histocompatibility complex.Am. J. Hum. Genet.73, 580–590 (2003).
- Miretti MM , WalshEC, KeX et al.: A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms.Am. J. Hum. Genet.76, 634–646 (2005).
- Newton JL , HarneySM, TimmsAE et al.: Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis.Arthritis Rheum.50, 2122–2129 (2004).